EYPT Q2 2021 Earnings — EyePoint Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

EYPTEyePoint Pharmaceuticals, Inc.

$1B

Q2 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$9M+118.7% YoY

Gross Profit

$7M78.6% margin

Operating Income

-$11M-121.8% margin

Net Income

-$10M-111.1% margin

EPS (Diluted)

$-0.35

QoQ Revenue Growth

+23.1%

Cash Flow

Operating Cash Flow

-$11M

Free Cash Flow

-$11M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$179M

Total Liabilities

$72M

Stockholders' Equity

$107M

Cash & Equivalents

$128M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$9M	$4M	+118.7%
Gross Profit	$7M	$4M	+95.7%
Operating Income	-$11M	-$11M	+1.6%
Net Income	-$10M	-$13M	+22.7%

Revenue Segments

Product

$9M50%

D E X Y C U Product

$5M26%

Y U T I Q Product

$4M24%